Investor Relations 2021

Key Business Performance Herzuma ✓ Retaining the highest market share among HerceptinⓇ biosimilars launched in EU while securing profitability by strategically participating in tenders ✓ Showing rapid penetration since the approval of 3-weekly regimen for breast cancer in Japan Market share of HerzumaⓇ in Europe Market share of HerzumaⓇ in Japan 100% 90% 80% 70% 60% 20% 15% 100% 80% 60% 19% 19% 18% 40% 16% 16% 15% 15% 13% 10% 47% 44% 39% 35% 25% 20% 10% 19.08 approval of 3-weekly regimen 12% 4% 5% 2% 1% 0% 0% 0% 0% 18.1Q 2Q 3Q 4Q 19.1Q 2Q 3Q 4Q 20.1Q 2Q 3Q 4Q 19.2Q 3Q 4Q 20.1Q 2Q 3Q 4Q 21.03 HerzumaⓇ Herceptin C Biosimilar D Biosimilar Note: market share is based on volume Source: IQVIA Note: market share is based on volume Source: IQVIA Herzuma® HerceptinⓇ Investor Relations 2021 10

View entire presentation